Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 dose-ranging trial in non-alcoholic steatohepatitis with liver fibrosis
ACTRN12621000080820Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Modality
- Peptides
- Countries
- 26
01
Overview
Phase 2, randomised, double-blind trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Histologic improvement in liver findings. Planned start May 2021; status: not yet recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on ACTRN12621000080820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000080820.